Immune checkpoint blockade provokes resident memory T cells to eliminate head and neck cancer.
editorial · Level V
Where this comes from
- Record sourced from PubMed, PMID 35931017.
- Also identified by DOI 10.1016/j.cell.2022.07.006.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
Immune checkpoint blockade is effective in treating many human cancers. In this issue of Cell, Luoma et al. show that tissue-resident memory T cells in head and neck cancers rapidly respond to immune checkpoint blockade, and they identify specific CD8<sup>+</sup> T cells in pretreatment blood that predict pathologic tumor regression.
Medical subject headings
- CD8-Positive T-Lymphocytes
- Head and Neck Neoplasms